Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.5.1881

Breast Cancer Molecular Subtypes and Associations with Clinicopathological Characteristics in Iranian Women, 2002-2011  

Kadivar, Maryam (Department of Pathology, Tehran University of Medical Sciences)
Mafi, Negar (Department of Pathology, Tehran University of Medical Sciences)
Joulaee, Azadeh (Department of Surgery, Shahid Beheshti University of Medical Sciences)
Shamshiri, Ahmad (Department of Epidemiology, Tehran University of Medical Sciences)
Hosseini, Niloufar (Department of Pathology, Tehran University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.5, 2012 , pp. 1881-1886 More about this Journal
Abstract
Breast cancer is a heterogeneous disease that is affected by ethnicity of patients. According to hormone receptor status and gene expression profiling, breast cancers are classified into four molecular subtypes, each showing distinct clinical behavior. Lack of sufficient data on molecular subtypes of breast cancer in Iran, prompted us to investigate the prevalence and the clinicopathological features of each subtype among Iranian women. A total of 428 women diagnosed with breast cancer from 2002 to 2011 were included and categorized into four molecular subtypes using immunohistochemistry. Prevalence of each subtype and its association with patients' demographics and tumor characteristics, such as size, grade, lymph-node involvement and vascular invasion, were investigated using Chi-square, analysis of variance and multivariate logistic regression. Luminal A was the most common molecular subtype (63.8%) followed by Luminal B (8.4%), basal-like (15.9%) and HER-2 (11.9%). Basal-like and HER-2 subtypes were mostly of higher grades while luminal A tumors were more of grade 1 (P<0.001). Vascular invasion was more prevalent in HER-2 subtype, and HER-2 positive tumors were significantly associated with vascular invasion (P=0.013). Using muti-variate analysis, tumor size greater than 5 cm and vascular invasion were significant predictors of 3 or more nodal metastases. Breast cancer was most commonly diagnosed in women around 50 years of age and the majority of patients had lymph node metastasis at the time of diagnosis. This points to the necessity for devising an efficient screening program for breast cancer in Iran. Further, prospective surveys are suggested to evaluate prognosis of different subtypes in Iranian patients.
Keywords
Breast cancer; molecular subtypes; immunohistochemistry; clinicopathological characteristics; Iran;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Al Tamimi DM ,Shawarby MA, Ahmed A, Hassan AK ,AlOdaini AA (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study. BMC Cancer, 10, 223.
2 American Cancer Society (2011). Global Cancer Facts & Figures 2nd Edition. Atlanta.
3 Anders C, Carey LA (2008). Understanding and treating triplenegative breast cancer. Oncology, 22, 1233-9.
4 Ben Abdelkrim S, Trabelsi A, Missaoui N, et al (2010). Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: A study of 194 patients. Pathol Res Pract, 206, 772-5.   DOI
5 Bhargava R, Striebel J, Beriwal S, et al (2009). Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J clin Exp Pathol, 2, 444-55.
6 Blackman DJ, Masi CM (2006). Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes?. J Clin Oncol, 24, 2170-8   DOI
7 Brenton JD, Carey LA, Ahmed AA, Caldas C (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23, 7350-60.   DOI
8 Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA, 295, 2492-502.   DOI   ScienceOn
9 Crabb SJ, Cheang MC, Leung S, et al (2008). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer, 8, 249-56.   DOI   ScienceOn
10 de Azambuja E, Cardoso F, de Castro G Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13.   DOI
11 Del Casar JM, Martín A, García C, et al (2008). Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol, 141, 147-52.   DOI
12 Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M (1996). Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res, 2, 147-54.
13 Harirchi I, Kolahdoozan S, Karbakhsh M, et al (2011). Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol, 22, 93-7.   DOI
14 Huber KE, Carey LA, Wazer DE (2009). Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol, 19, 204-10.   DOI
15 Huo D, Ikpatt F, Khramtsov A, et al (2009). Population differences in breast cancer: survey indigenous african women reveals over-representation of triple-negative breast cancer. J Clin Oncol, 27, 4515-21.   DOI
16 Ihemelandu CU, Leffall LD Jr, Dewitty RL,et al (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res, 143, 109-18.   DOI
17 Ma CX, Sanchez CG, Ellis MJ (2009). Predicting endocrine therapy responsiveness in breast cancer. Oncology, 23, 133-42.
18 Iranian Annual of National Cancer Registration Report (2008-2009). Islamic Republic of Iran, Ministry of health and medical education, Center for disease control & prevention, non-communicable diseases unit, cancer office.
19 Keshgegian AA, Cnaan A (1995). Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol, 104, 42-9.   DOI
20 Kim MJ, Ro JY, Ahn SH, et al (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER2/neu-over expressing phenotypes. Hum Pathol , 37, 1217-26.   DOI   ScienceOn
21 Miron L, Marinca A, Marinca M, Miron I (2008). Triple-negative breast cancer-towards a new entity. Rev Med Chir Soc Med Nat Iasi, 112, 51-8.
22 Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91.   DOI
23 Munoz M, Fernández-Acenero MJ, Martín S, Schneider J (2009). Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet, 280, 43-8.   DOI
24 Nguyen PL, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol, 26, 2373-8.   DOI
25 Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF (2006). Molecular classification of breast cancer: limitations and potential. Oncologist, 11, 868-77.   DOI
26 Spitale A, Mazzola P, Soldini D, Mazzucchelli L Bordoni A (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland. Ann Oncol, 20, 628-35.   DOI   ScienceOn
27 Salhia B, Tapia C, Ishak EA, et al (2011). Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Women's Health, 11, 44.   DOI
28 Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.   DOI   ScienceOn
29 Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.   DOI   ScienceOn
30 Tian XS, Cong MH, Zhou WH, et al (2008). Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie, 31, 610-4.   DOI
31 Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer, 97, 1321-3.   DOI
32 Wiechmann L, Sampson M, Stempel M, et al (2009). Presenting features of breast cancer differ by molecular subtype (2009). Ann Surg Oncol, 16, 2705-10.   DOI
33 Yang XR, Sherman ME, Rimm DL, et al (2007). Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev, 16, 439-43.   DOI   ScienceOn
34 Zaha DC, Lazar E, Lazureanu C (2010). Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol, 51, 85-9.
35 Zhao J, Liu H, Wang M, et al (2009). Characteristics and prognosis for molecular breast cancer subtypes in chinese women. J Surg Oncol, 100, 89-94.   DOI